🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525165-52-00
Authorised Phase I

A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin® (somatropin) Delivery and Taken Up Into the Blood in Healthy Adults

2026-525165-52-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pfizer Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Hormonal diseases
Decision date
25/03/2026
Enrollment target
26
Sites
Belgium

Condition studied

Growth hormone deficiency

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525165-52-00 on CTIS ↗ ← All trials in the EU